It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Space travel induces stresses that contribute to health problems, as well as inducing the expression of Nrf2 (NF-E2-related factor-2) target genes that mediate adaptive responses to oxidative and other stress responses. The volume of epididymal white adipose tissue (eWAT) in mice increases during spaceflight, a change that is attenuated by Nrf2 knockout. We conducted metabolome analyses of plasma from wild-type and Nrf2 knockout mice collected at pre-flight, in-flight and post-flight time points, as well as tissues collected post-flight to clarify the metabolic responses during and after spaceflight and the contribution of Nrf2 to these responses. Plasma glycerophospholipid and sphingolipid levels were elevated during spaceflight, whereas triacylglycerol levels were lower after spaceflight. In wild-type mouse eWAT, triacylglycerol levels were increased, but phosphatidylcholine levels were decreased, and these changes were attenuated in Nrf2 knockout mice. Transcriptome analyses revealed marked changes in the expression of lipid-related genes in the liver and eWAT after spaceflight and the effects of Nrf2 knockout on these changes. Based on these results, we concluded that space stress provokes significant responses in lipid metabolism during and after spaceflight; Nrf2 plays critical roles in these responses.
Akira Uruno et al. report the volume of epidydimal white adipose tissue and plasma glycerophospholipid and sphingolipid levels in mice increase during spaceflight. These metabolic and physiological changes were largely driven by Nrf2 (NF-E2-related factor-2), ultimately providing a mechanistic target for altering lipid metabolism on Earth and the Great Beyond.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
2 Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
3 JEM Utilization Center, Human Spaceflight Technology Directorate, JAXA, Tsukuba, Japan (GRID:grid.69566.3a)
4 Tohoku University, Department of Health Record Informatics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
5 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
6 Tohoku University, Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
7 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University, Advanced Research Center for Innovations in Next-GEneration Medicine (INGEM), Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
8 Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Center for Radioisotope Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
9 Tohoku University Graduate School of Medicine, Division of Oxygen Biology, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
10 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University, Advanced Research Center for Innovations in Next-GEneration Medicine (INGEM), Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
11 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Department of Molecular Hematology, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943)
12 Translational Research Program, Fred Hutchinson Cancer Research Center, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622)
13 JEM Utilization Center, Human Spaceflight Technology Directorate, JAXA, Tsukuba, Japan (GRID:grid.270240.3)